vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and QUINSTREET, INC (QNST). Click either name above to swap in a different company.
QUINSTREET, INC is the larger business by last-quarter revenue ($287.8M vs $183.1M, roughly 1.6× Amphastar Pharmaceuticals, Inc.). QUINSTREET, INC runs the higher net margin — 17.4% vs 13.3%, a 4.1% gap on every dollar of revenue. On growth, QUINSTREET, INC posted the faster year-over-year revenue change (1.9% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $20.7M). Over the past eight quarters, QUINSTREET, INC's revenue compounded faster (53.2% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
QUINSTREET, INCQNSTEarnings & Financial Report
QuinStreet, Inc. is a publicly traded online marketing company based in Foster City, California. The company helps generate web traffic for clients by acquiring popular domain names.
AMPH vs QNST — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $287.8M |
| Net Profit | $24.4M | $50.2M |
| Gross Margin | 46.8% | 9.6% |
| Operating Margin | 19.4% | 0.4% |
| Net Margin | 13.3% | 17.4% |
| Revenue YoY | -1.8% | 1.9% |
| Net Profit YoY | -35.7% | 3342.5% |
| EPS (diluted) | $0.51 | $0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $287.8M | ||
| Q3 25 | $191.8M | $285.9M | ||
| Q2 25 | $174.4M | — | ||
| Q1 25 | $170.5M | $269.8M | ||
| Q4 24 | $186.5M | $282.6M | ||
| Q3 24 | $191.2M | $279.2M | ||
| Q2 24 | $182.4M | $198.3M | ||
| Q1 24 | $171.8M | $168.6M |
| Q4 25 | $24.4M | $50.2M | ||
| Q3 25 | $17.4M | $4.5M | ||
| Q2 25 | $31.0M | — | ||
| Q1 25 | $25.3M | $4.4M | ||
| Q4 24 | $38.0M | $-1.5M | ||
| Q3 24 | $40.4M | $-1.4M | ||
| Q2 24 | $37.9M | $-2.2M | ||
| Q1 24 | $43.2M | $-7.0M |
| Q4 25 | 46.8% | 9.6% | ||
| Q3 25 | 51.4% | 9.4% | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | 10.3% | ||
| Q4 24 | 46.5% | 9.5% | ||
| Q3 24 | 53.3% | 10.2% | ||
| Q2 24 | 52.2% | 8.8% | ||
| Q1 24 | 52.4% | 8.5% |
| Q4 25 | 19.4% | 0.4% | ||
| Q3 25 | 13.2% | 1.7% | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | 1.8% | ||
| Q4 24 | 24.2% | -0.5% | ||
| Q3 24 | 29.8% | -0.4% | ||
| Q2 24 | 30.3% | -0.7% | ||
| Q1 24 | 27.9% | -3.2% |
| Q4 25 | 13.3% | 17.4% | ||
| Q3 25 | 9.0% | 1.6% | ||
| Q2 25 | 17.8% | — | ||
| Q1 25 | 14.8% | 1.6% | ||
| Q4 24 | 20.4% | -0.5% | ||
| Q3 24 | 21.1% | -0.5% | ||
| Q2 24 | 20.8% | -1.1% | ||
| Q1 24 | 25.1% | -4.2% |
| Q4 25 | $0.51 | $0.87 | ||
| Q3 25 | $0.37 | $0.08 | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | $0.08 | ||
| Q4 24 | $0.74 | $-0.03 | ||
| Q3 24 | $0.78 | $-0.02 | ||
| Q2 24 | $0.73 | $-0.04 | ||
| Q1 24 | $0.81 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $107.0M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $294.4M |
| Total Assets | $1.6B | $493.0M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $107.0M | ||
| Q3 25 | $276.2M | $101.3M | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | $81.8M | ||
| Q4 24 | $221.6M | $57.8M | ||
| Q3 24 | $250.5M | $25.0M | ||
| Q2 24 | $217.8M | $50.5M | ||
| Q1 24 | $289.6M | $39.6M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $294.4M | ||
| Q3 25 | $776.7M | $246.7M | ||
| Q2 25 | $757.5M | — | ||
| Q1 25 | $751.3M | $235.5M | ||
| Q4 24 | $732.3M | $224.3M | ||
| Q3 24 | $727.7M | $219.8M | ||
| Q2 24 | $713.3M | $216.8M | ||
| Q1 24 | $672.4M | $215.0M |
| Q4 25 | $1.6B | $493.0M | ||
| Q3 25 | $1.7B | $442.6M | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | $417.2M | ||
| Q4 24 | $1.6B | $409.6M | ||
| Q3 24 | $1.5B | $401.2M | ||
| Q2 24 | $1.5B | $368.5M | ||
| Q1 24 | $1.6B | $349.3M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $21.6M |
| Free Cash FlowOCF − Capex | $24.6M | $20.7M |
| FCF MarginFCF / Revenue | 13.4% | 7.2% |
| Capex IntensityCapex / Revenue | 4.5% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.35× | 0.43× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $106.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $21.6M | ||
| Q3 25 | $52.6M | $19.6M | ||
| Q2 25 | $35.6M | — | ||
| Q1 25 | $35.1M | $30.1M | ||
| Q4 24 | $29.0M | $38.7M | ||
| Q3 24 | $60.0M | $-13.7M | ||
| Q2 24 | $69.1M | $16.6M | ||
| Q1 24 | $55.3M | $4.1M |
| Q4 25 | $24.6M | $20.7M | ||
| Q3 25 | $47.2M | $18.4M | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | $29.5M | ||
| Q4 24 | $16.6M | $38.2M | ||
| Q3 24 | $46.2M | $-14.1M | ||
| Q2 24 | $63.1M | $15.4M | ||
| Q1 24 | $46.5M | $2.9M |
| Q4 25 | 13.4% | 7.2% | ||
| Q3 25 | 24.6% | 6.4% | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | 10.9% | ||
| Q4 24 | 8.9% | 13.5% | ||
| Q3 24 | 24.1% | -5.1% | ||
| Q2 24 | 34.6% | 7.8% | ||
| Q1 24 | 27.1% | 1.7% |
| Q4 25 | 4.5% | 0.3% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | 0.2% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 3.3% | 0.6% | ||
| Q1 24 | 5.1% | 0.7% |
| Q4 25 | 1.35× | 0.43× | ||
| Q3 25 | 3.03× | 4.32× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 6.82× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
QNST
| Financial Service | $216.8M | 75% |
| Home Services And Other Revenue | $71.0M | 25% |
